ESTRO 2023 - Abstract Book

S1148

Digital Posters

ESTRO 2023

PO-1420 Cardiac metastasis in uterine cervical cancer: Systematic review and case report

I. Simek 1 , A. Kranz 1 , S. Alina 1 , J. Knoth 1 , M. Vögele-Kadletz 2 , A. Spannbauer 3 , J. Bergler-Klein 4 , J. Widder 1 , M. Schmid 1

1 Medical University of Vienna, Radiooncology, Vienna, Austria; 2 Medical University of Vienna, Cardiac Surgery, Vienna, Austria; 3 Medical University of Vienna, Cardiology, Vienna, Austria; 4 Medical University of Vienna, Cadiology, Vienna, Austria Purpose or Objective To present a systematic review - based on a case report - on patients with cardiac metastasis from cervical cancer. Materials and Methods A systematic literature search employing PRISMA guidelines focused on case reports about cardiac metastases from cervical cancer. PubMed was queried using the following search terms: (((*card* OR heart) AND metast*) AND ((cervic* OR uter*) AND cancer)); Scopus, using ("cardiac metastasis" AND "cervical cancer"), Web of Science with ((TS=(uter* AND cervi*)) AND (TS=(card* AND metast*))), CENTRAL with (Disease: cervical cancer/cervix cancer/cervix dysplasia/cervical dysplasia/; Additional terms: card* metast*) and ClinicalTrials.gov via “Disease: cervical cancer/cervix cancer/cervix dysplasia/cervical dysplasia; Additional terms: card* metast*”. Searches were conducted in December 2019, an e-mail-alert was created for PubMed and Web of Science that was followed until May 2022. Based on the search results, a title search was conducted, followed by an abstract search and a full text search. The search was supplemented by cross-referencing the cited references of relevant papers. Results Eighty-one papers were identified describing 86 cases in total. Cardiac metastasis occurred at all stages of cervical cancer and in all age groups. Median time from initial diagnosis to diagnosis of cardiac metastasis was 12 months, ranging from no time to more than ten years. Dyspnea (69%), chest pain (31%), deteriorating general condition and arrhythmias (both 11%) were the main reported symptoms due to cardiac metastasis, whilst 9% of patients had no symptoms. ECG findings were reported in 51 cases and were pathologic in 31 patients. The cardiac mass was most frequently detected by transthoracic echography. The most common tumor histology was squamous cell carcinoma. Chemotherapy and surgical interventions were the main treatment modalities. Median time of survival after diagnosis of cardiac metastasis was 3 months, with 14% of patients surviving for more than 1 year and 21% of patients surviving for less than a month. Of the cases with known survival time (n=63), median survival was 5 months in patients who had cardiac surgery (n=25) versus 2.5 months in those who had no cardiac surgery (n=38).

Conclusion This largest review on cardiac metastases from cervical cancer confirmed the heart as a very infrequent site of metastasis. There are <100 cases described in the literature with very poor prognosis and undefined clinical management.

PO-1421 Image-guided brachytherapy for cervical cancer – Experience at Carlos Van Buren Hospital

L. González Abascal 1 , G. Lazcano Álvarez 2 , J. Solis Campos 2 , B. Tudela Staub 2 , G. Veillon Contreras 2 , J. Olivares Gonzalez 3

1 Universidad de Valparaiso, Radiation Oncology, Valparaíso, Chile; 2 Universidad de Valparaiso, Radiation Oncology, Valparaiso, Chile; 3 Hospital Base de Valdivia, Radiation Oncology, Valdivia, Chile Purpose or Objective External beam radiation therapy with concomitant chemotherapy followed by adaptive image-guided brachytherapy (IGABT) is the standard of care for patients with locally advanced cervical cancer (LACC). The purpose of this study is to describe the outcomes of the IGABT protocol at the radiation oncology department of the Carlos Van Buren Hospital (Valparaíso, Chile) Materials and Methods A retrospective cohort study was carried out to analyze the results of patients with LACC treated with concomitant radiochemotherapy followed by IGABT with curative intent between 2019 and June 2021.

Results The cohort includes 106 patients, whose characteristics are presented in Table 1.